Selective inhibitors of prostaglandin endoperoxide synthase-2

Abstract

The present invention provides a compound of the formula wherein when X is S; R is selected from the group consisting of CH3, CH2CH3, CH2Ph, (CH2)2Ph, (CH2)2CH3, (CH2)3CH3, (CH2)4CH3, CH2)5CH3, (CH2)6CH3, (CH2)2O(CH2)3CH3, CH2HC═CH(CH2)3CH3, CH2C≡C(CH2)3CH3, CH2C≡C(CH2)2CH3, CH2C≡CCH2CH3, CH2C≡CCH3, CH2C≡CH, CH2C≡C(CH2)4CH3, CH2C≡C(CH2)5CH3, CH2C≡C(CH2)6CH3, (CH2)2C≡C(CH2)2CH3, CH(Ch3)C≡C(CH2)3CH3, (CH2)6I, (CH2)6Br, (CH2)5Br, (CH2)5COOH and (CH2)5OCOCH3, and R′ is selected from the group consisting of CH3, CF3, CH2Cl, CH2Br, CH2CH3, NH2, and OSO2CH3; wherein when R is CH3, R′ can not be CH3 or CH2Cl; wherein when R is CH2CH3, R′ can not be CH3; wherein when X is Se, R is (CH2)6CH3, and R′ is CH3 or a pharmaceutically acceptable salt or hydrate thereof; and wherein when X is O, R is CH2C≡C(CH2)3CH3, and R′ is CH3 or a pharmaceutically acceptable salt or hydrate thereof. Also provided is a method of inhibiting the synthesis of prostaglandin endoperoxide synthase-2 (PGHS-2) in a mammal.

Dependencies are inferred from the claim text.